Amy Schacterle - 07 Jan 2026 Form 4 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Role: Chief Regulatory Officer
Signature: /s/ Derek Meisner, Attorney-in-Fact
Issuer symbol: ABOS
Transactions as of: 07 Jan 2026
Net transactions value: -$2,176
Form type: 4
Filing time: 09 Jan 2026, 16:38:43 UTC
Previous filing: 07 Jan 2025
Next filing: 21 Jan 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Schacterle Amy	Chief Regulatory Officer	C/O ACUMEN PHARMACEUTICALS, INC., 1210-1220 WASHINGTON STREET, SUITE 210, NEWTON	/s/ Derek Meisner, Attorney-in-Fact	09 Jan 2026	0002042021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ABOS	Common Stock	Sale	$2,176	-1,097	-12%	$1.98	7,703	07 Jan 2026	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2025.
F2	The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9550 to $2.0100. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Content

Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2025.

The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.9550 to $2.0100. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.